转移性-话题@MedSci

#转移性#

975篇内容 | 3406人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1386616, encodeId=408e1386616fa, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=树突状细胞疗法ilixadencel获得FDA授予的再生医学高级疗法称号，用于治疗转移性肾细胞癌, objectType=article, longId=193622, objectId=7ffb19362230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ffb19362230, replyNumber=0, likeNumber=84, createdTime=2020-05-08, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ffb19362230, moduleTitle=树突状细胞疗法ilixadencel获得FDA授予的再生医学高级疗法称号，用于治疗转移性肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ffb19362230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386615, encodeId=f95b13866156c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期, objectType=article, longId=192958, objectId=e2db19295879, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2db19295879, replyNumber=0, likeNumber=76, createdTime=2020-04-27, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2db19295879, moduleTitle=阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2db19295879)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386614, encodeId=735d138661427, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Oncol Lett：帕米膦酸二钠可有效治疗老年晚期转移性骨癌, objectType=article, longId=192874, objectId=6fba1928e400, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fba1928e400, replyNumber=0, likeNumber=66, createdTime=2020-04-25, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fba1928e400, moduleTitle=Oncol Lett：帕米膦酸二钠可有效治疗老年晚期转移性骨癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fba1928e400)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386613, encodeId=8f1613866130b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Cancer Med：二氯化镭-223联合激素治疗激素受体阳性骨转移性乳腺癌的II期研究, objectType=article, longId=192853, objectId=22aa1928533a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22aa1928533a, replyNumber=0, likeNumber=85, createdTime=2020-04-25, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22aa1928533a, moduleTitle=Cancer Med：二氯化镭-223联合激素治疗激素受体阳性骨转移性乳腺癌的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22aa1928533a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386612, encodeId=2d92138661268, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=J Nucl Med：177 Lu-PSMA-617在转移性去势抵抗性前列腺癌中的剂量测定, objectType=article, longId=192821, objectId=a90819282151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a90819282151, replyNumber=0, likeNumber=77, createdTime=2020-04-24, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a90819282151, moduleTitle=J Nucl Med：177 Lu-PSMA-617在转移性去势抵抗性前列腺癌中的剂量测定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a90819282151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386611, encodeId=f68b13866117d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌, objectType=article, longId=192476, objectId=9a771924e693, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a771924e693, replyNumber=0, likeNumber=29, createdTime=2020-04-20, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a771924e693, moduleTitle=FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a771924e693)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386610, encodeId=78b513866105c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=转移性三阴性乳腺癌治疗获突破：性抗体偶联疗法疗效显著, objectType=article, longId=192310, objectId=61191923102d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61191923102d, replyNumber=0, likeNumber=77, createdTime=2020-04-16, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61191923102d, moduleTitle=转移性三阴性乳腺癌治疗获突破：性抗体偶联疗法疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61191923102d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386609, encodeId=72c6138660939, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NMPA批准百济神州的抗PD-1单抗替雷利珠，用于治疗局部晚期或转移性尿道上皮癌, objectType=article, longId=192250, objectId=940019225097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=940019225097, replyNumber=0, likeNumber=62, createdTime=2020-04-16, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=940019225097, moduleTitle=NMPA批准百济神州的抗PD-1单抗替雷利珠，用于治疗局部晚期或转移性尿道上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=940019225097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386608, encodeId=3e2b13866086c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌, objectType=article, longId=191734, objectId=89b6191e3439, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89b6191e3439, replyNumber=0, likeNumber=89, createdTime=2020-04-10, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89b6191e3439, moduleTitle=FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89b6191e3439)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386607, encodeId=ed95138660e28, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Sci Transl Med：转移性前列腺癌新突破：免疫检查点抑制剂彰显成效！, objectType=article, longId=191332, objectId=39b819133230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39b819133230, replyNumber=0, likeNumber=59, createdTime=2020-04-04, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39b819133230, moduleTitle=Sci Transl Med：转移性前列腺癌新突破：免疫检查点抑制剂彰显成效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39b819133230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386606, encodeId=757f138660673, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌, objectType=article, longId=191239, objectId=94ff191239b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94ff191239b4, replyNumber=0, likeNumber=63, createdTime=2020-04-03, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94ff191239b4, moduleTitle=拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94ff191239b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386605, encodeId=e63d1386605d2, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=一例特殊非转移性去势抵抗性前列腺癌患者，个体化新型内分泌治疗后生存良好！, objectType=article, longId=190970, objectId=6cd81909e0c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cd81909e0c0, replyNumber=0, likeNumber=84, createdTime=2020-03-29, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cd81909e0c0, moduleTitle=一例特殊非转移性去势抵抗性前列腺癌患者，个体化新型内分泌治疗后生存良好！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cd81909e0c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386604, encodeId=c7841386604cc, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌, objectType=article, longId=190853, objectId=1643190853f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1643190853f0, replyNumber=0, likeNumber=91, createdTime=2020-03-27, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1643190853f0, moduleTitle=抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1643190853f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386603, encodeId=81451386603ed, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=日本批准CABOMETYX（cabozantinib）治疗无法切除的或转移性肾细胞癌, objectType=article, longId=190852, objectId=502a190852b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=502a190852b7, replyNumber=0, likeNumber=73, createdTime=2020-03-27, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=502a190852b7, moduleTitle=日本批准CABOMETYX（cabozantinib）治疗无法切除的或转移性肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=502a190852b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386602, encodeId=904c138660298, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Clin Cancer Res：癌症新发现！基于cfDNA的检测手段，大大提高了转移性乳腺癌的诊断敏感度！, objectType=article, longId=190272, objectId=49a11902e294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49a11902e294, replyNumber=0, likeNumber=72, createdTime=2020-03-20, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49a11902e294, moduleTitle=Clin Cancer Res：癌症新发现！基于cfDNA的检测手段，大大提高了转移性乳腺癌的诊断敏感度！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49a11902e294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386601, encodeId=1e61138660120, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗, objectType=article, longId=190232, objectId=9131190232f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9131190232f7, replyNumber=0, likeNumber=65, createdTime=2020-03-19, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9131190232f7, moduleTitle=Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9131190232f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386600, encodeId=a347138660022, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet oncol：帕妥珠单抗+曲妥珠单抗+多西他赛治疗HER2+转移性乳腺癌的8年预后, objectType=article, longId=190229, objectId=fd1819022915, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd1819022915, replyNumber=0, likeNumber=72, createdTime=2020-03-19, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd1819022915, moduleTitle=Lancet oncol：帕妥珠单抗+曲妥珠单抗+多西他赛治疗HER2+转移性乳腺癌的8年预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd1819022915)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386599, encodeId=c5781386599f6, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, objectType=article, longId=189823, objectId=597d18982326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597d18982326, replyNumber=0, likeNumber=58, createdTime=2020-03-13, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597d18982326, moduleTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=597d18982326)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386598, encodeId=db601386598d1, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Clinical Cancer Res：Cabozantinib联合ADT治疗激素幼稚性转移性前列腺癌, objectType=article, longId=189552, objectId=e06a189552a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e06a189552a1, replyNumber=0, likeNumber=44, createdTime=2020-03-10, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e06a189552a1, moduleTitle=Clinical Cancer Res：Cabozantinib联合ADT治疗激素幼稚性转移性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e06a189552a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386597, encodeId=5428138659e4b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=超声诊断颈部转移性乳腺外Paget病1例, objectType=article, longId=189243, objectId=cedb18924318, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cedb18924318, replyNumber=0, likeNumber=77, createdTime=2020-03-04, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cedb18924318, moduleTitle=超声诊断颈部转移性乳腺外Paget病1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cedb18924318)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性

2020-05-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

树突状细胞疗法ilixadencel获得FDA授予的再生医学高级疗法称号，用于治疗转移性肾细胞癌

2020-05-08

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期

2020-04-27

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Oncol Lett：帕米膦酸二钠可有效治疗老年晚期转移性骨癌

2020-04-25

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Cancer Med：二氯化镭-223联合激素治疗激素受体阳性骨转移性乳腺癌的II期研究

2020-04-25

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

J Nucl Med：177 Lu-PSMA-617在转移性去势抵抗性前列腺癌中的剂量测定

2020-04-24

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌

2020-04-20

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

转移性三阴性乳腺癌治疗获突破：性抗体偶联疗法疗效显著

2020-04-16

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NMPA批准百济神州的抗PD-1单抗替雷利珠，用于治疗局部晚期或转移性尿道上皮癌

2020-04-16

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌

2020-04-10

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Sci Transl Med：转移性前列腺癌新突破：免疫检查点抑制剂彰显成效！

2020-04-04

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌

2020-04-03

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

一例特殊非转移性去势抵抗性前列腺癌患者，个体化新型内分泌治疗后生存良好！

2020-03-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌

2020-03-27

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

日本批准CABOMETYX（cabozantinib）治疗无法切除的或转移性肾细胞癌

2020-03-27

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Clin Cancer Res：癌症新发现！基于cfDNA的检测手段，大大提高了转移性乳腺癌的诊断敏感度！

2020-03-20

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗

2020-03-19

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet oncol：帕妥珠单抗+曲妥珠单抗+多西他赛治疗HER2+转移性乳腺癌的8年预后

2020-03-19

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果

2020-03-13

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Clinical Cancer Res：Cabozantinib联合ADT治疗激素幼稚性转移性前列腺癌

2020-03-10

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

超声诊断颈部转移性乳腺外Paget病1例

2020-03-04

科室
- - 订阅+
  - 更多科室
工具
服务